Multitarget drugs: The present and the future of cancer therapy

Annalisa Petrelli, Giorgio Valabrega

Research output: Contribution to journalArticle

Abstract

Target therapies for the treatment of human cancers have revolutionized the concept of oncological medicine. This type of therapeutic approach is directed to the inhibition of molecular targets that play a pivotal role in tumor progression - such as tyrosine kinase receptors (TKIs) controlling cell proliferation and survival - mainly by means of compounds able to block their activity. In the beginning, the aim of target therapies was specifically to hit a single molecule expressed in neoplastic cells. Now the prevailing idea is that inhibiting both cancer cells and cells of the stroma supporting the tumor would gain better results in fighting the disease. Therefore, the single-target therapy is fading in favor of a multitarget approach and the new generation of TKIs is selected on the basis of their ability simultaneously to target different molecules. This review summarizes the molecular basis of multitarget therapies and the most relevant results obtained in different cancer types.

Original languageEnglish
Pages (from-to)589-600
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Volume10
Issue number4
DOIs
Publication statusPublished - Mar 2009

Fingerprint

Pharmaceutical Preparations
Neoplasms
Therapeutics
Receptor Protein-Tyrosine Kinases
Cell Survival
Cell Proliferation
Medicine

Keywords

  • Cancer therapy
  • Clinical trials
  • Multitarget
  • Oncogene addiction
  • Stroma
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Multitarget drugs : The present and the future of cancer therapy. / Petrelli, Annalisa; Valabrega, Giorgio.

In: Expert Opinion on Pharmacotherapy, Vol. 10, No. 4, 03.2009, p. 589-600.

Research output: Contribution to journalArticle

@article{cb9d32f9e77c450b9275cf5a744799ce,
title = "Multitarget drugs: The present and the future of cancer therapy",
abstract = "Target therapies for the treatment of human cancers have revolutionized the concept of oncological medicine. This type of therapeutic approach is directed to the inhibition of molecular targets that play a pivotal role in tumor progression - such as tyrosine kinase receptors (TKIs) controlling cell proliferation and survival - mainly by means of compounds able to block their activity. In the beginning, the aim of target therapies was specifically to hit a single molecule expressed in neoplastic cells. Now the prevailing idea is that inhibiting both cancer cells and cells of the stroma supporting the tumor would gain better results in fighting the disease. Therefore, the single-target therapy is fading in favor of a multitarget approach and the new generation of TKIs is selected on the basis of their ability simultaneously to target different molecules. This review summarizes the molecular basis of multitarget therapies and the most relevant results obtained in different cancer types.",
keywords = "Cancer therapy, Clinical trials, Multitarget, Oncogene addiction, Stroma, Tyrosine kinase inhibitors",
author = "Annalisa Petrelli and Giorgio Valabrega",
year = "2009",
month = "3",
doi = "10.1517/14656560902781907",
language = "English",
volume = "10",
pages = "589--600",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

TY - JOUR

T1 - Multitarget drugs

T2 - The present and the future of cancer therapy

AU - Petrelli, Annalisa

AU - Valabrega, Giorgio

PY - 2009/3

Y1 - 2009/3

N2 - Target therapies for the treatment of human cancers have revolutionized the concept of oncological medicine. This type of therapeutic approach is directed to the inhibition of molecular targets that play a pivotal role in tumor progression - such as tyrosine kinase receptors (TKIs) controlling cell proliferation and survival - mainly by means of compounds able to block their activity. In the beginning, the aim of target therapies was specifically to hit a single molecule expressed in neoplastic cells. Now the prevailing idea is that inhibiting both cancer cells and cells of the stroma supporting the tumor would gain better results in fighting the disease. Therefore, the single-target therapy is fading in favor of a multitarget approach and the new generation of TKIs is selected on the basis of their ability simultaneously to target different molecules. This review summarizes the molecular basis of multitarget therapies and the most relevant results obtained in different cancer types.

AB - Target therapies for the treatment of human cancers have revolutionized the concept of oncological medicine. This type of therapeutic approach is directed to the inhibition of molecular targets that play a pivotal role in tumor progression - such as tyrosine kinase receptors (TKIs) controlling cell proliferation and survival - mainly by means of compounds able to block their activity. In the beginning, the aim of target therapies was specifically to hit a single molecule expressed in neoplastic cells. Now the prevailing idea is that inhibiting both cancer cells and cells of the stroma supporting the tumor would gain better results in fighting the disease. Therefore, the single-target therapy is fading in favor of a multitarget approach and the new generation of TKIs is selected on the basis of their ability simultaneously to target different molecules. This review summarizes the molecular basis of multitarget therapies and the most relevant results obtained in different cancer types.

KW - Cancer therapy

KW - Clinical trials

KW - Multitarget

KW - Oncogene addiction

KW - Stroma

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=65649131585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65649131585&partnerID=8YFLogxK

U2 - 10.1517/14656560902781907

DO - 10.1517/14656560902781907

M3 - Article

C2 - 19284362

AN - SCOPUS:65649131585

VL - 10

SP - 589

EP - 600

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 4

ER -